Abstract:Abstract Background The introduction of anti-PD-1 antibody has greatly improved the clinical outcomes of patients with non-small cell lung cancer(NSCLC). Here we retrospectively analyzed the efficacy of PD-1 antibody-based therapy in patients with locally advanced un-operable or metastatic NSCLC patients and report an association between peripheral blood biomarkers with clinical response in these patients. Methods We conducted a single-center study by including medical record data for NSCLC patients treated with PD-1 antibody first-line or posterior-line either as monotherapy or in combination with chemotherapy. The patients enrolled from 2020 to 2022. Dynamic evaluation of multiple Th1 and Th2 cytokines in the blood serum, as well as analysis of the phenotype of T cells from peripheral blood, was conducted to explore the correlation between cytokines levels, T cell phenotype, and clinical response. Results 88 stage IIIA-IV NSCLC patients were enrolled. 60(68.18%) patients achieved partial response(PR), 13 (14.77%) patients were stable(SD) and 15(17.05%) patients had progressed disease (PD). The disease control rate (DCR) was 82.95%. Our results suggested a significant reduction (P = 0.002, P < 0.005) of lymphocyte absolute counts after treatment in the patients with disease progression(PD). Higher levels of IFN-γ(P = 0.023,P < 0.05), TNF-α(P = 0.00098,P < 0.005 ), IL-4 (P = 0.0031 ,P < .0.005), IL-5 (P = 0.0015,P < 0.005) and IL-10 ( P = 0.036 ,P < 0.05) were detected in peripheral blood prior to the treatment in PR group comparing with PD group.. Besides, those patients with high IL-5、IL-13、IL-4、IL-6、IFN-γ and TNF-α(> 10ng/ml) had superior PFS than those with low IL-5、IL-13、 IL-4、IL-6、IFN-γ and TNF-α(< 10ng/ml). Moreover, the expression of PD-1 expression on CD8 + Tcells was positive associated with the clinical response between response patients (PR)and non-response(SD + PD)patients(P = 0.042, P < 0.05). Conclusions The findings of this study imply that the decrease in absolute blood lymphocyte counts after treatment is correlated to the progression of the disease. It is possible that serum cytokine concentrations can forecast the effectiveness and survival rate of anti-PD-1 blockade therapy in NSCLC patients. In addition, the expression of PD-1 expression on CD8 + Tcells was positive associated with the better clinical response as well. The findings of our study indicated the potential of peripheral blood biomarkers analysis to offer predictive value of PD-1-targeted treatments to NSCLC patients. Large prospective studies need to further clarify the value of these biomarkers.

Characterization of pre- and on-treatment soluble immune mediators and the tumor microenvironment in NSCLC patients receiving PD-1/L1 inhibitor monotherapy

CD57+CD8+T Cells and Response to PD-1/PD-L1 Blockade in Patients with NSCLC

Molecular characterization of clinical responses to PD-1/PD-L1 inhibitors in non-small cell lung cancer: Predictive value of multidimensional immunomarker detection for the efficacy of PD-1 inhibitors in Chinese patients.

Soluble PD-L1 As a Predictor of the Response to EGFR-TKIs in Non-small Cell Lung Cancer Patients with EGFR Mutations.

Soluble immune checkpoint factors reflect exhaustion of antitumor immunity and response to PD-1 blockade

Serum immune mediators as novel predictors of response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients with high tissue-PD-L1 expression

Peripheral blood biomarkers associated with combination of immune checkpoint blockade plus chemotherapy in NSCLC

Low Infiltration of CD8+ PD-L1+ T Cells and M2 Macrophages Predicts Improved Clinical Outcomes After Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Carcinoma

Predictive value of the biomarker of peripheral blood of NSCLC patients responding to anti-PD-1 treatment

Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.

Comprehensive Analysis of Immune Responses to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer

CD137+ and regulatory T cells as independent prognostic factors of survival in advanced non-oncogene addicted NSCLC patients treated with immunotherapy as first-line

Clinical markers predict the efficacy of several immune checkpoint inhibitors in patients with non-small cell lung cancer in China

CXCL13 Positive Cells Localization Predict Response to Anti-PD-1/PD-L1 in Pulmonary Non-Small Cell Carcinoma

Pretreatment radiomic biomarker for immunotherapy responder prediction in stage IB-IV NSCLC (LCDigital-IO Study): a multicenter retrospective study

Pretreatment Radiomic Biomarker for Immunotherapy Responder Prediction in IB-IV Stage NSCLC: A Multi-Center Retrospective Study

Clinical Characteristics Correlate with Outcomes of Immunotherapy in Advanced Non-Small Cell Lung Cancer

Molecular Characteristics and Pretreatment Neutrophil-to-Lymphocyte Ratio as Predictors of Durable Clinical Benefit from Immune Checkpoint Inhibition in Non-Small Cell Lung Cancer

Peripheral blood markers predictive of outcome and immune-related adverse events in advanced non-small cell lung cancer treated with PD-1 inhibitors

Distinct circulating cytokine/chemokine profiles correlate with clinical benefit of immune checkpoint inhibitor monotherapy and combination therapy in advanced non‐small cell lung cancer

Peripheral CD4 + T cell signatures in predicting the responses to anti-PD-1/PD-L1 monotherapy for Chinese advanced non-small cell lung cancer